Efficacy and tolerability of a custom-made ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Efficacy and tolerability of a custom-made narval mandibular repositioning device for the treatment of obstructive sleep apnea: orcades study 2-year follow-up data
Author(s) :
Attali, Valerie [Auteur]
Vecchierini, Marie-Francoise [Auteur]
Collet, Jean-Marc [Auteur]
D''''ortho, Marie-Pia [Auteur]
Goutorbe, Frederic [Auteur]
Kerbrat, Jean-Baptiste [Auteur]
Leger, Damien [Auteur]
Lavergne, Florent [Auteur]
Meriaux, Christelle [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Monteyrol, Pierre-Jean [Auteur]
Morin, Laurent [Auteur]
Mullens, Eric [Auteur]
Pigearias, Bernard [Auteur]
Martin, Francis [Auteur]
Tordjman, Fabienne [Auteur]
Khemliche, Hauria [Auteur]
Lerousseau, Lionel [Auteur]
Meurice, Jean-Claude [Auteur]
Vecchierini, Marie-Francoise [Auteur]
Collet, Jean-Marc [Auteur]
D''''ortho, Marie-Pia [Auteur]
Goutorbe, Frederic [Auteur]
Kerbrat, Jean-Baptiste [Auteur]
Leger, Damien [Auteur]
Lavergne, Florent [Auteur]
Meriaux, Christelle [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Monteyrol, Pierre-Jean [Auteur]
Morin, Laurent [Auteur]
Mullens, Eric [Auteur]
Pigearias, Bernard [Auteur]
Martin, Francis [Auteur]
Tordjman, Fabienne [Auteur]
Khemliche, Hauria [Auteur]
Lerousseau, Lionel [Auteur]
Meurice, Jean-Claude [Auteur]
Journal title :
Sleep medicine
Abbreviated title :
Sleep Med.
Volume number :
63
Pages :
64-74
Publication date :
2019-06-12
ISSN :
1878-5506
Keyword(s) :
Sleep apnea
Mandibular advancement device
Sleep disorder breathing
Mandibular advancement device
Sleep disorder breathing
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Mandibular repositioning device (MRD) therapy is an alternative to continuous positive airway pressure (CPAP). The Orkney Complex Disease Study-ORCADES study is assessing the long-term efficacy and tolerability of MRD ...
Show more >Mandibular repositioning device (MRD) therapy is an alternative to continuous positive airway pressure (CPAP). The Orkney Complex Disease Study-ORCADES study is assessing the long-term efficacy and tolerability of MRD therapy in obstructive sleep apnoea syndrome (OSAS); two-year follow-up data are presented. OSAS patients who refused or were noncompliant with CPAP were fitted with a custom-made computer-aided design/computer-aided manufacturing (CAD/CAM) bi-block MRD (ResMed, Narval CC™); mandibular advancement was individually titrated. Sleep and respiratory parameters were determined at baseline, 3-6 months, and two years. The primary endpoint was treatment success (percentage of patients achieving a ≥50% reduction in the apnoea-hypopnoea index [AHI]). Of 315 enrolled patients, 237 remained on MRD treatment at two years, and 197 had follow-up data. The treatment success rate at two years was 67%; AHI <5/h, <10/h and <15/h was achieved in 30%, 56% and 72% of patients, respectively. On multivariate analysis, ≥50% decrease in AHI at 3-6 months and absence of nocturia at 3-6 months were significant predictors of MRD treatment continuation. Adverse events were generally mild, and the majority occurred in the first year of treatment. Two years' treatment with an MRD was effective and well tolerated in patients with mild to severe OSAS who refused or were intolerant of CPAP.Show less >
Show more >Mandibular repositioning device (MRD) therapy is an alternative to continuous positive airway pressure (CPAP). The Orkney Complex Disease Study-ORCADES study is assessing the long-term efficacy and tolerability of MRD therapy in obstructive sleep apnoea syndrome (OSAS); two-year follow-up data are presented. OSAS patients who refused or were noncompliant with CPAP were fitted with a custom-made computer-aided design/computer-aided manufacturing (CAD/CAM) bi-block MRD (ResMed, Narval CC™); mandibular advancement was individually titrated. Sleep and respiratory parameters were determined at baseline, 3-6 months, and two years. The primary endpoint was treatment success (percentage of patients achieving a ≥50% reduction in the apnoea-hypopnoea index [AHI]). Of 315 enrolled patients, 237 remained on MRD treatment at two years, and 197 had follow-up data. The treatment success rate at two years was 67%; AHI <5/h, <10/h and <15/h was achieved in 30%, 56% and 72% of patients, respectively. On multivariate analysis, ≥50% decrease in AHI at 3-6 months and absence of nocturia at 3-6 months were significant predictors of MRD treatment continuation. Adverse events were generally mild, and the majority occurred in the first year of treatment. Two years' treatment with an MRD was effective and well tolerated in patients with mild to severe OSAS who refused or were intolerant of CPAP.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2021-06-23T13:44:02Z